Praxis Precision Medicines (PRAX) EBIT Margin: 2023-2025
Historic EBIT Margin for Praxis Precision Medicines (PRAX) over the last 3 years, with Sep 2025 value amounting to -1,770.82%.
- Praxis Precision Medicines' EBIT Margin rose 1704871.00% to -1,770.82% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,316.76%, marking a year-over-year increase of 890225.00%. This contributed to the annual value of -2,340.29% for FY2024, which is 282412.00% up from last year.
- Per Praxis Precision Medicines' latest filing, its EBIT Margin stood at -1,770.82% for Q3 2025, which was down 15.00% from -1,539.82% recorded in Q2 2025.
- Praxis Precision Medicines' 5-year EBIT Margin high stood at -856.97% for Q4 2024, and its period low was -18,819.54% during Q3 2024.
- Moreover, its 3-year median value for EBIT Margin was -5,399.22% (2023), whereas its average is -5,953.34%.
- As far as peak fluctuations go, Praxis Precision Medicines' EBIT Margin slumped by 1,336,740bps in 2024, and later soared by 1,704,871bps in 2025.
- Over the past 3 years, Praxis Precision Medicines' EBIT Margin (Quarterly) stood at -5,399.22% in 2023, then soared by 454,225bps to -856.97% in 2024, then skyrocketed by 1,704,871bps to -1,770.82% in 2025.
- Its last three reported values are -1,770.82% in Q3 2025, -1,539.82% for Q2 2025, and -1,375.70% during Q1 2025.